Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1995 1
1996 1
1998 2
1999 1
2000 3
2001 6
2002 4
2003 6
2004 8
2005 6
2006 7
2007 8
2008 9
2009 10
2010 22
2011 20
2012 18
2013 18
2014 9
2015 5
2016 8
2017 12
2018 9
2019 10
2020 13
2021 9
2022 10
Text availability
Article attribute
Article type
Publication date

Search Results

211 results
Results by year
Filters applied: . Clear all
Page 1
Trial of Cinpanemab in Early Parkinson's Disease.
Lang AE, Siderowf AD, Macklin EA, Poewe W, Brooks DJ, Fernandez HH, Rascol O, Giladi N, Stocchi F, Tanner CM, Postuma RB, Simon DK, Tolosa E, Mollenhauer B, Cedarbaum JM, Fraser K, Xiao J, Evans KC, Graham DL, Sapir I, Inra J, Hutchison RM, Yang M, Fox T, Budd Haeberlein S, Dam T; SPARK Investigators. Lang AE, et al. Among authors: siderowf ad. N Engl J Med. 2022 Aug 4;387(5):408-420. doi: 10.1056/NEJMoa2203395. N Engl J Med. 2022. PMID: 35921450 Clinical Trial.
Neurofilament Light Chain as a Biomarker for Cognitive Decline in Parkinson Disease.
Aamodt WW, Waligorska T, Shen J, Tropea TF, Siderowf A, Weintraub D, Grossman M, Irwin D, Wolk DA, Xie SX, Trojanowski JQ, Shaw LM, Chen-Plotkin AS. Aamodt WW, et al. Among authors: siderowf a. Mov Disord. 2021 Dec;36(12):2945-2950. doi: 10.1002/mds.28779. Epub 2021 Sep 4. Mov Disord. 2021. PMID: 34480363 Free PMC article.
Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson's disease.
Jennings D, Huntwork-Rodriguez S, Henry AG, Sasaki JC, Meisner R, Diaz D, Solanoy H, Wang X, Negrou E, Bondar VV, Ghosh R, Maloney MT, Propson NE, Zhu Y, Maciuca RD, Harris L, Kay A, LeWitt P, King TA, Kern D, Ellenbogen A, Goodman I, Siderowf A, Aldred J, Omidvar O, Masoud ST, Davis SS, Arguello A, Estrada AA, de Vicente J, Sweeney ZK, Astarita G, Borin MT, Wong BK, Wong H, Nguyen H, Scearce-Levie K, Ho C, Troyer MD. Jennings D, et al. Among authors: siderowf a. Sci Transl Med. 2022 Jun 8;14(648):eabj2658. doi: 10.1126/scitranslmed.abj2658. Epub 2022 Jun 8. Sci Transl Med. 2022. PMID: 35675433
Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression.
Mollenhauer B, Dakna M, Kruse N, Galasko D, Foroud T, Zetterberg H, Schade S, Gera RG, Wang W, Gao F, Frasier M, Chahine LM, Coffey CS, Singleton AB, Simuni T, Weintraub D, Seibyl J, Toga AW, Tanner CM, Kieburtz K, Marek K, Siderowf A, Cedarbaum JM, Hutten SJ, Trenkwalder C, Graham D. Mollenhauer B, et al. Among authors: siderowf a. Mov Disord. 2020 Nov;35(11):1999-2008. doi: 10.1002/mds.28206. Epub 2020 Aug 15. Mov Disord. 2020. PMID: 32798333 Free PMC article.
Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.
Simuni T, Uribe L, Cho HR, Caspell-Garcia C, Coffey CS, Siderowf A, Trojanowski JQ, Shaw LM, Seibyl J, Singleton A, Toga AW, Galasko D, Foroud T, Tosun D, Poston K, Weintraub D, Mollenhauer B, Tanner CM, Kieburtz K, Chahine LM, Reimer A, Hutten SJ, Bressman S, Marek K; PPMI Investigators. Simuni T, et al. Among authors: siderowf a. Lancet Neurol. 2020 Jan;19(1):71-80. doi: 10.1016/S1474-4422(19)30319-9. Epub 2019 Oct 31. Lancet Neurol. 2020. PMID: 31678032 Free PMC article.
Biomarkers of neurodegeneration and glial activation validated in Alzheimer's disease assessed in longitudinal cerebrospinal fluid samples of Parkinson's disease.
Bartl M, Dakna M, Galasko D, Hutten SJ, Foroud T, Quan M, Marek K, Siderowf A, Franz J, Trenkwalder C, Mollenhauer B; Parkinson’s Progression Markers Initiative. Bartl M, et al. Among authors: siderowf a. PLoS One. 2021 Oct 7;16(10):e0257372. doi: 10.1371/journal.pone.0257372. eCollection 2021. PLoS One. 2021. PMID: 34618817 Free PMC article. Clinical Trial.
Author Response.
Jennings D, Siderowf A, Stern M, Seibyl J, Eberly S, Oakes D, Marek K. Jennings D, et al. Among authors: siderowf a. Neurology. 2015 Jun 2;84(22):2292. Neurology. 2015. PMID: 26230002 No abstract available.
Screening questionnaires for parkinsonism: a systematic review.
Dahodwala N, Siderowf A, Baumgarten M, Abrams A, Karlawish J. Dahodwala N, et al. Among authors: siderowf a. Parkinsonism Relat Disord. 2012 Mar;18(3):216-24. doi: 10.1016/j.parkreldis.2011.09.003. Epub 2011 Sep 17. Parkinsonism Relat Disord. 2012. PMID: 21930414 Free PMC article. Review.
211 results